#1 Clinical Trials Search in Europe

Ly3454738

Clinical trials are studying Ly3454738 in adults with moderate-to-severe atopic dermatitis, also called eczema. These trials are looking at whether Ly3454738 is effective and how it compares with placebo in people who have not used biologic or small-molecule treatments before.

Table of Contents

Trial overview

The available trial studied Ly3454738 in adults with moderate-to-severe atopic dermatitis, which is a long-term skin condition also called eczema.[1]

This was an interventional study, which means the researchers gave a study treatment and measured the results.[1]

The trial was in Phase 2, a stage that looks for early signs that a treatment may work and continues to monitor safety.[1]

Who could join the study

The study was for adult participants with moderate-to-severe atopic dermatitis.[1]

It focused on people who were biologic-and-small-molecule naïve, meaning they had not used those treatment types before.[1]

This helps researchers understand how Ly3454738 performs in a group that has not been treated with these newer medicine types before.[1]

What was studied

The trial compared Ly3454738 with placebo, which is a look-alike treatment that does not contain the active study drug.[1]

The brief study summary says the main goal was to compare the efficacy, or how well the treatment works, of Ly3454738 versus placebo in this patient group.[1]

The trial included treatment given by subcutaneous injection, which means a shot under the skin.[1]

Trial endpoints and results being measured

The main endpoint was the percentage of participants who achieved EASI-75.[1]

EASI stands for Eczema Area and Severity Index, a score used to measure how severe eczema is.[1]

EASI-75 means the score improved by at least 75%, which shows a large improvement in eczema signs and symptoms.[1]

Trial design and treatment groups

The trial was designed as a comparison between Ly3454738 and placebo.[1]

The source data also lists topical treatments and sodium chloride solution in the intervention record, but the clearest study objective provided is the comparison of Ly3454738 versus placebo in moderate-to-severe atopic dermatitis.[1]

Because the source only gives a brief summary, the main patient-relevant detail is that the study tested whether Ly3454738 could improve eczema outcomes better than placebo in adults who had not used biologic or small-molecule therapies before.[1]

Study status and size

The trial is marked as completed.[1]

A total of 262 participants were enrolled.[1]

This makes it a moderate-sized Phase 2 study focused on eczema treatment research.[1]

Trial ID Phase Condition studied Status Enrollment
2022-502888-38-00 Phase 2 Atopic dermatitis Completed 262

FAQ

  • What is being studied in Ly3454738 trials? The trial is studying Ly3454738 in adults with moderate-to-severe atopic dermatitis. It is looking at whether the treatment helps improve eczema symptoms compared with placebo.
  • Who can take part in the study? The study is for adult participants with moderate-to-severe atopic dermatitis. It focuses on people who are biologic-and-small-molecule naïve, meaning they have not used those treatment types before.
  • What phase is the Ly3454738 trial? The trial is a Phase 2 study. Phase 2 trials usually check early signs of how well a treatment works and continue to watch safety.
  • What result is the trial measuring? The main result is EASI-75, which means at least a 75% improvement in the Eczema Area and Severity Index. This score is used to measure how severe eczema is and how much it improves.
  • What is the status of the trial? The study is completed. It enrolled 262 participants.

Ongoing Clinical Trials on Ly3454738

  • Study of LY3454738 for Treating Moderate-to-Severe Atopic Dermatitis in Adults

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Hungary Italy Poland

Glossary

  • Atopic dermatitis: A long-term skin condition, also called eczema, that can cause dry, itchy, and inflamed skin.
  • Moderate-to-severe: A level of illness that is more than mild and can cause a bigger impact on daily life.
  • Biologic-and-small-molecule naïve: A person who has not used biologic medicines or small-molecule treatments before.
  • Placebo: A treatment that looks like the study treatment but does not contain the active drug.
  • Phase 2: A clinical trial stage that looks for early signs that a treatment may work and continues safety checks.
  • Interventional study: A study where researchers give a treatment and measure what happens.
  • EASI: Eczema Area and Severity Index, a score used to measure how bad eczema is.
  • EASI-75: A result meaning the eczema score improved by at least 75%.
  • Enrollment: The number of people who joined the study.
  • Subcutaneous injection: A shot given under the skin.

References

  1. https://clinicaltrials.gov/study/2022-502888-38-00